Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley T. Crooke unloaded 15,500 shares of the company’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $35.45, for a total value of $549,475.00. Following the sale, the chief executive officer now directly owns 6,941 shares in the company, valued at approximately $246,058. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 1.24% during mid-day trading on Friday, hitting $36.13. 1,681,585 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a one year low of $22.25 and a one year high of $62.66. The stock’s 50-day moving average is $32.11 and its 200-day moving average is $37.2. The company’s market cap is $4.254 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. On average, analysts predict that ISIS Pharmaceuticals will post $-0.75 earnings per share for the current fiscal year.

A number of research firms have recently commented on ISIS. Analysts at Laidlaw initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday. They set a “buy” rating on the stock. Separately, analysts at Laidlow & Co. initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $52.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. ISIS Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $42.64.

Receive News & Ratings for ISIS Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ISIS Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.